stevanato group Archives - Medical Design Sourcing

8 drug delivery innovations you should know

Innovations in drug delivery never stop and, over the past 12 months or so, a wide variety have come under the spotlight.

Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing just how many ways we can deliver therapeutics.

About a year ago, we clued in readers to a list of six drug delivery innovations they should know. Here, we provide a couple of updates on those and try to introduce a few more developments that you should know:

The latest in automated insulin delivery tech

Automated insulin delivery represents one of the most high-profile markets in drug delivery, with the technology providing potentially life-saving therapy for people with diabetes.

The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]Last year’s roundup included the already FDA-cleared Omn…

Stevanato Group unveils on-body drug delivery device

The Vertiva on-body delivery system. [Image courtesy of Stevanato Group]Stevanato Group (NYSE:STVN) today unveiled Vertiva, the latest release of its patented on-body drug delivery system.

Piombino Dese, Italy-based Stevanato Group designed Vertiva with the ability to switch between basal and bolus injections. It has suitability for a wide range of subcutaneous therapies.

In March, Stevanato Group announced plans to bring this on-body device to market through a collaboration with Thermo Fisher Scientific. The companies plan to offer the platform as an integrated device and fill-and-finish solution.

The company designed Vertiva with a single-use pod featuring a pre-filled and pre-loaded 3mL ISO cartridge. It also comes with a multi-use controller for potential sustainability and affordability benefits. Both parts communicate through a patented, magnetically coupled drive mechanism.

Stevanato Group said its device can adapt to different delivery profil…

Stevanato Group, Thermo Fisher to bring on-body drug delivery system to market

[Image courtesy of Stevanato Group]Stevanato Group (NYSE:STVN) today announced a collaboration with Thermo Fisher Scientific (NYSE:TMO) on drug delivery technology.

The partnership aims to bring a fully integrated, on-body delivery system platform for subcutaneous administration to market.

Stevanato Group said the device will be semi-reusable and provide micro-precision basal doses and full-content bolus injections. The company intends for the flexible, customizable platform to administer a wide range of therapies.

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group, Recipharm partner on pre-filled syringes for inhaled therapeutics

Stevanato Group (NYSE:STVN) today announced a collaboration with Recipharm to manufacture pre-fillable syringes for soft mist inhalers.

Piombino Dese, Italy-based Stevanato Group plans to lend manufacturing experience to support production of the syringes. As part of the collaboration, it intends to provide and manufacture its Alba glass pre-fillable syringe. Stevanato Group will assemble Alba with the integrated spray module (ISMTM) of Recipharm’s soft mist inhaler. Together, this creates the “pre-filled syringe inhaler” (PFSITM).

In the partnership, Stevanato Group takes responsibility for the complete primary drug package. Recipharm’s focus centers around the design and manufacture of the spray technology, the inhalation device and the fill/finish effort.

Get the ful…

Stevanato Group, Owen Mumford to collaborate on Aidaptus auto-injector

[Image from Owen Mumford]Stevanato Group (NYSE:STVN) announced today that it signed an exclusive agreement with Owen Mumford for its auto-injector technology.

Piombino Dese, Italy-based Stevanato Group’s agreement makes it an exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. Under the agreement, Stevanato Group will mold the components for the technology and provide final and sub-assembly equipment, along with market-leading pre-filled syringes.

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group, Bexson expand partnership for wearable drug delivery device

[Image from Stevanato Group]Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration.

Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder (PTSD).

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group acquires facility set to become manufacturing hub in China

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant.

Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development.

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group extends licensing agreement with Haselmeier for pen injector tech

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it signed an extension to a licensing agreement with Haselmeier over its pen injector technology.

Piombino Dese, Italy-based Stevanato Group’s license extension gives the company exclusivity to offer the Axis-D pen injector technology in support of a broader range of drugs for its biopharma customers beyond diabetes, including areas such as obesity, cardiovascular disease, gastrointestinal disorders, pain management, neurological disorder, arthritis and more.

Get the full story at our sister site, Drug Delivery Business News.

FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump

Bexson is developing a wearable infusion pump with Stevanato Group. [Image from Bexson]Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy.

Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group.

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group expands corporate headquarters

[Image from Stevanato Group]Stevanato Group (NYSE:STVN) announced today that it expanded its corporate headquarters with a new facility in Italy.

Based in Piombino Dese, Italy, Stevanato Group expects its 6,750-square meter facility to support the optimization of its industrial footprint while advancing operations and growth within the company.

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group beats The Street in Q3, raises guidance

Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast.

The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of 36.5%.

Get the full story at our sister site, Drug Delivery Business News.

Stevanato Group is constructing a new facility in Indiana

Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana.

Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023.

Get the full story at our sister site, Drug Delivery Business News.